Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Aug 22, 2022 10:47am
232 Views
Post# 34911241

RE:RE:RE:RE:My cousin

RE:RE:RE:RE:My cousinThey do recruit those they think have three months yet to live. From my very non-medical perspective, I did not really think she had that much time left but they let her into the trial anyway and they are the doctors, not me. She looked pretty bad when Gettysburg first evaluated her but I immagine that is the  norm. She then had to wait a month without any treatment following her previous chemo before starting TH-1902 and she deteriorated even further during that time, again mostly due to an inability to eat and drink what she needed to survive. She also had a complication called ascites which may have played a role in her demise. If I had to say what led directly to her passing, I would guess malnutrition brought on by her cancer. Ascites may have played a role in her lack of desire to eat but she also could be her own worst enemy on that front at times. She was in the hospital for the last week of her life, and they earnestly tried to build her back up nutritionally, but it was seemingly too late. May TH-1902 eventually help beat back this awful disease that has claimed so many lives too early. 

palinc2000 wrote: sorry for your loss.!!! I think they recruit only patients with a life expectancy of at least 3 months   .....Unfortunately fate decided otherwise


<< Previous
Bullboard Posts
Next >>